First-generation antipsychotic (substituted benzamide)

Sulpiride

Brand names: Dolmatil, Sulpor

Sulpiride is a substituted benzamide first-generation antipsychotic used in schizophrenia, with predominantly negative symptoms sometimes targeted at lower doses.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a selective antagonist of dopamine D2 and D3 receptors, with relatively little activity at other receptor types.

Prescribing in practice

It can prolong the QT interval and cause hyperprolactinaemia, with effects such as galactorrhoea, menstrual disturbance and sexual dysfunction.
It is largely renally excreted, so reduced doses and caution are needed in renal impairment.
Extrapyramidal effects and neuroleptic malignant syndrome can occur, as with other antipsychotics.

Monitoring

Monitor for extrapyramidal symptoms, prolactin-related effects, renal function and QT interval where cardiac risk factors exist.

Counselling the patient

Report any breast swelling or discharge, menstrual changes or sexual difficulties to your doctor.
Tell your doctor if you develop muscle stiffness, tremor or restlessness.
Do not stop the medicine suddenly without advice.

Evidence & guidelines

Sulpiride is an established antipsychotic, and its use is informed by NICE guidance on the management of psychosis and schizophrenia.

Reference: NICE CG178; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways